3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Myeloid
1
Classical hematology
1
Conditions
Colorectal Neoplasms
4
Venous Thromboembolism
2
Thrombocythemia, Essential
1
Testicular Neoplasms
1
Stomach Neoplasms
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Polycythemia Vera
1
Ovarian Neoplasms
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms
1
Hemorrhage
1
Fallopian Tube Neoplasms
1
Colorectal Neoplasms, Hereditary Nonpolyposis
1
Breast Neoplasms
1
Interventions
ruxolitinib
6
Specimen Handling
6
Stem Cell Transplantation
5
Cyclophosphamide
4
fludarabine
3
Mycophenolic Acid
3
Biopsy
3
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
3
Whole-Body Irradiation
2
Tacrolimus
2
Sirolimus
2
Methotrexate
2
Melphalan
2
Hematopoietic Stem Cell Transplantation
2
Blood Component Removal
2
thymoglobulin
1
talazoparib
1
tagraxofusp
1
reparixin
1
poly ICLC
1
piperine
1
pegylated granulocyte colony-stimulating factor
1
merphos
1
letermovir
1
fludarabine phosphate
1
fedratinib
1
demethoxycurcumin
1
daratumumab
1
bomedemstat
1
axatilimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Primary Myelofibrosis
×
Aspirin
×
Clear all
NCT05198960
2026-03-20
AVAJAK
University Hospital, Brest
Phase 3
Recruiting
1,308 enrolled